{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-008972","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.624336+00:00","generated_at":"2026-06-06T15:08:53.996572+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Revelation Biosciences posts updated corporate presentation; no material new details disclosed","bullets":["Presentation dated Jan 30, 2024, posted on company website; no financial or pipeline specifics in filing.","Company focuses on developing innovative therapeutics for unmet medical needs.","No guidance, milestones, or material events announced in the presentation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-008972","json":"https://secwatch.observer/filing/0000950170-24-008972.json","markdown":"https://secwatch.observer/filing/0000950170-24-008972.md","text":"https://secwatch.observer/filing/0000950170-24-008972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024008972/0000950170-24-008972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024008972/revb-20240130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:08:53.996572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}